Stock 301263 GUANGDONG TAIENKANG PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Guangdong Taienkang Pharmaceutical Co., Ltd.

Equities

301263

CNE1000058X0

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 03:30:00 07/06/2024 am IST 		5-day change 1st Jan Change
12.99 CNY +2.93% Intraday chart for Guangdong Taienkang Pharmaceutical Co., Ltd. -5.53% -20.45%
14/05 Guangdong Taienkang Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2023 CI
22/04 Guangdong Taienkang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2022 2023 2024 2025
Capitalization 1 7,683 6,948 5,501 -
Enterprise Value (EV) 1 7,683 6,948 5,501 5,501
P/E ratio 41.1 x 43 x 17.6 x 13.1 x
Yield 2.15% 1.84% 5.39% 5.39%
Capitalization / Revenue 9.81 x 9.13 x 4.71 x 3.66 x
EV / Revenue 9.81 x 9.13 x 4.71 x 3.66 x
EV / EBITDA 33.3 x 30.4 x 12.6 x 9.39 x
EV / FCF - - - -
FCF Yield - - - -
Price to Book 4.14 x 3.88 x 2.49 x 2.09 x
Nbr of stocks (in thousands) 4,25,498 4,25,498 4,23,512 -
Reference price 2 18.06 16.33 12.99 12.99
Announcement Date 26/04/23 22/04/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025
Net sales 1 - 783.5 760.8 1,168 1,505
EBITDA 1 - 230.9 228.8 435 586
EBIT 1 - 209.2 190.9 392 537
Operating Margin - 26.7% 25.1% 33.56% 35.68%
Earnings before Tax (EBT) 1 - 207.4 192.3 394 540
Net income 1 120.1 174.6 160.2 315 422
Net margin - 22.29% 21.06% 26.97% 28.04%
EPS 2 0.3778 0.4389 0.3800 0.7400 0.9900
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share 2 - 0.3889 0.3000 0.7000 0.7000
Announcement Date 26/04/22 26/04/23 22/04/24 - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) - 11.4% 8.75% 14.2% 16%
ROA (Net income/ Total Assets) - 11.7% - 13.2% 15.1%
Assets 1 - 1,490 - 2,386 2,795
Book Value Per Share 2 - 4.360 4.210 5.220 6.210
Cash Flow per Share 2 - 0.3500 0.2200 0.4900 0.8100
Capex 1 - 89.9 200 90 94
Capex / Sales - 11.47% 26.28% 7.71% 6.25%
Announcement Date 26/04/22 26/04/23 22/04/24 - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Guangdong Taienkang Pharmaceutical Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
12.99
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
GUANGDONG TAIENKANG PHARMACEUTICAL CO., LTD. Stock Guangdong Taienkang Pharmaceutical Co., Ltd.
-20.45% 738M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+45.82% 754B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.95% 630B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.16% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.86% 331B
ABBVIE INC. Stock AbbVie Inc.
+9.32% 298B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.45% 250B
NOVARTIS AG Stock Novartis AG
+11.88% 217B
ROCHE HOLDING AG Stock Roche Holding AG
-0.78% 216B
AMGEN INC. Stock Amgen Inc.
+5.90% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 301263 Stock
  4. Financials Guangdong Taienkang Pharmaceutical Co., Ltd.